Effect of Ivabradine on Exercise Capacity After Heart Transplantation
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates whether treatment with ivabradine compared to placebo can improve
exercise capacity in long-term heart transplant recipients with cardiac allograft
vasculopathy and elevated heart rate at rest.
Patients will receive treatment with either ivabradin or placebo for a period of 12 weeks.